Business Description
ATAI Life Sciences NV
ISIN : NL0015000DX5
Compare
Compare
Traded in other countries / regions
ATAI.USA9VC.GermanyATAI.Mexico IPO Date
2022-02-28Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.61 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.87 | |||||
| Beneish M-Score | 0.19 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 27.6 | |||||
| 3-Year EPS without NRI Growth Rate | 14.9 | |||||
| 3-Year FCF Growth Rate | -57.7 | |||||
| 3-Year Book Growth Rate | 34.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 99.57 | |||||
| 9-Day RSI | 97.5 | |||||
| 14-Day RSI | 94.87 | |||||
| 6-1 Month Momentum % | -33.57 | |||||
| 12-1 Month Momentum % | -30.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.81 | |||||
| Quick Ratio | 5.81 | |||||
| Cash Ratio | 4.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3 | |||||
| Shareholder Yield % | -1.58 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -31092.15 | |||||
| Net Margin % | -38852.87 | |||||
| FCF Margin % | -23610.38 | |||||
| ROE % | -61.51 | |||||
| ROA % | -50.07 | |||||
| ROIC % | -91.48 | |||||
| ROC (Joel Greenblatt) % | -4268.63 | |||||
| ROCE % | -52.3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 845 | |||||
| PB Ratio | 1.95 | |||||
| Price-to-Tangible-Book | 1.94 | |||||
| EV-to-EBIT | -1.84 | |||||
| EV-to-Forward-EBIT | -0.86 | |||||
| EV-to-EBITDA | -1.84 | |||||
| EV-to-Forward-EBITDA | -1.79 | |||||
| EV-to-Revenue | 691.72 | |||||
| EV-to-Forward-Revenue | 295.3 | |||||
| EV-to-FCF | -2.76 | |||||
| Price-to-Net-Current-Asset-Value | 4.57 | |||||
| Price-to-Net-Cash | 8.44 | |||||
| Earnings Yield (Greenblatt) % | -54.34 | |||||
| FCF Yield % | -27.5 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ATAI Life Sciences NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 6.06 | ||
| EPS (TTM) (MXN) | -14.427 | ||
| Beta | 0 | ||
| Volatility % | 39.72 | ||
| 14-Day RSI | 94.87 | ||
| 14-Day ATR (MXN) | 0.645973 | ||
| 20-Day SMA (MXN) | 24.3925 | ||
| 12-1 Month Momentum % | -30.23 | ||
| 52-Week Range (MXN) | 22.9 - 37.32 | ||
| Shares Outstanding (Mil) | 167.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ATAI Life Sciences NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ATAI Life Sciences NV Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
ATAI Life Sciences NV Frequently Asked Questions
What is ATAI Life Sciences NV(MEX:ATAI)'s stock price today?
The current price of MEX:ATAI is MXN32.85. The 52 week high of MEX:ATAI is MXN37.32 and 52 week low is MXN22.90.
When is next earnings date of ATAI Life Sciences NV(MEX:ATAI)?
The next earnings date of ATAI Life Sciences NV(MEX:ATAI) is 2025-02-13 Est..
Does ATAI Life Sciences NV(MEX:ATAI) pay dividends? If so, how much?
ATAI Life Sciences NV(MEX:ATAI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers